Lava Therapeutics Nv (LVTX)
$1.5158
Market is closed - opens 8 PM, 01 Dec 2023
Insights on Lava Therapeutics Nv
Decreasing Revenue
Revenue is down for the last 2 quarters, 5.13M → 53.0K (in $), with an average decrease of 99.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -14.99M → -8.83M (in $), with an average increase of 30.9% per quarter
Vs SGEN
In the last 1 year, Seagen, Inc. has given 76.2% return, outperforming this stock by 153.7%
Performance
- $1.48$1.52$1.52
2.57%
Downside
Day's Volatility :2.57%
Upside
0.0%
- $1.13$7.38$1.52
25.66%
Downside
52 Weeks Volatility :84.69%
Upside
79.4%
Returns
| Period | Lava Therapeutics Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.84% | -1.7% | 0.0% |
6 Months | -20.22% | 2.1% | 0.0% |
1 Year | -77.54% | -5.8% | -6.0% |
3 Years | -89.4% | 18.7% | -3.7% |
Highlights
Market Capitalization | 39.7M |
Book Value | $2.08 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.92 |
Wall Street Target Price | 6.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -20239.62% |
Return On Assets TTM | -23.62% |
Return On Equity TTM | -68.44% |
Revenue TTM | 9.1M |
Revenue Per Share TTM | 0.34 |
Quarterly Revenue Growth YOY | -99.7% |
Gross Profit TTM | -20.7M |
EBITDA | -48.7M |
Diluted Eps TTM | -1.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.8 |
EPS Estimate Next Year | -1.79 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.17 |
Analyst Recommendation
Buy
90%Buy
9%Hold
0
0%Sell
Based on 11 Wall street analysts offering stock ratings for Lava Therapeutics Nv(by analysts ranked 0 to 5 stars)
Based on 11 analyst
- Current
- 1M Ago
- 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 348.61%
Current $1.52
Target $6.80
Technicals Summary
Sell
Neutral
Buy
Lava Therapeutics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lava Therapeutics Nv | 28.46% | -20.22% | -77.54% | -89.4% | -89.4% |
 Moderna, Inc. | 1.97% | -39.54% | -57.19% | -44.9% | 317.74% |
 Regeneron Pharmaceuticals, Inc. | 4.11% | 12.67% | 8.22% | 60.25% | 115.31% |
 Novo Nordisk A/s | 4.26% | 28.93% | 61.48% | 201.7% | 342.4% |
 Seagen, Inc. | -0.54% | 9.52% | 76.18% | 20.18% | 233.4% |
 Vertex Pharmaceuticals Incorporated | -3.93% | 9.64% | 10.62% | 54.06% | 92.15% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lava Therapeutics Nv | 0.25 | NA | NA | -1.8 | -0.68 | -0.24 | 0.0 | 2.08 |
Moderna, Inc. | 24.73 | NA | 0.0 | -11.52 | -0.22 | -0.07 | 0.0 | 35.32 |
Regeneron Pharmaceuticals, Inc. | 22.78 | 22.78 | 9.01 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
Novo Nordisk A/s | 43.04 | 43.04 | 2.03 | 2.62 | 0.89 | 0.22 | 0.01 | 20.77 |
Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
Vertex Pharmaceuticals Incorporated | 26.52 | 26.52 | 0.41 | 15.04 | 0.23 | 0.14 | 0.02 | 64.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lava Therapeutics Nv | Buy | $39.7M | -89.4% | 0.25 | 0.0% |
Moderna, Inc. | Buy | $29.6B | 317.74% | 24.73 | -38.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $87.0B | 115.31% | 22.78 | 30.47% |
Novo Nordisk A/s | Buy | $470.4B | 342.4% | 43.04 | 35.11% |
Seagen, Inc. | Hold | $40.0B | 233.4% | NA | -32.61% |
Vertex Pharmaceuticals Incorporated | Buy | $91.0B | 92.15% | 26.52 | 35.94% |
Company Information
Organization | Lava Therapeutics Nv |
Employees | 69 |
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Industry | Healthcare |
